NGM Bio to Participate in Upcoming Investor Conferences
April 20 2022 - 4:05PM
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a
biotechnology company focused on discovering and developing
transformative therapeutics for patients, today announced that
David J. Woodhouse, Ph.D., Chief Executive Officer, will present an
overview of the company and provide a business update at the
following upcoming virtual investor conferences.
Raymond James LILRB/ILT Symposium Tuesday,
April 26, 2022, 1:30 pm ET
B. Riley Securities' 2022 Virtual Neurology &
Ophthalmology ConferenceThursday, April 28, 2022, 10:30 am
ET
Live webcasts of the presentations will be available under the
Investors and Media section of NGM Bio’s website at
https://ir.ngmbio.com/events-presentations. A replay of each
presentation will be archived on NGM Bio’s site for at least 30
days following the event.
Abbreviations (in Alphabetical Order)
ILT=Immunoglobulin-Like Transcript; LILRB= Leukocyte
Immunoglobulin-Like Receptor Subfamily B
About NGM Biopharmaceuticals, Inc.
NGM Bio is focused on discovering and developing novel,
life-changing medicines for people whose health and lives have been
disrupted by disease. The company’s biology-centric drug discovery
approach aims
to seamlessly integrate interrogation of complex
disease-associated biology and protein engineering expertise to
unlock proprietary insights that are leveraged to generate
promising product candidates and enable their rapid advancement
into proof-of-concept studies. As explorers on the frontier of
life-changing science, NGM Bio aspires to operate one of the most
productive research and development engines in the
biopharmaceutical industry. All therapeutic candidates in the NGM
Bio pipeline have been generated by its in-house discovery engine,
with a disease-agnostic mindset, always led by biology and
motivated by unmet patient need. Today, the company has seven
programs in active development, including four in Phase 2 or
2b studies, across three therapeutic areas:
cancer, retinal diseases and liver and
metabolic diseases. Visit us at www.ngmbio.com for more
information.
Investor Contact: |
Media Contact: |
Brian Schoelkopf |
media@ngmbio.com |
ir@ngmbio.com |
|
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jul 2024 to Aug 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Aug 2023 to Aug 2024